Aelin Therapeutics awarded €2.3 million VLAIO research grant

| General news | No Comments
Funding will enable accelerated development of unique Pept™-in-based cancer therapeuticsLeuven, BELGIUM – 9 July 2020 – Aelin Therapeutics NV, an emerging biotechnology company focused on the discovery and development of…

Aelin Therapeutics appoints Alexander Scheer, Ph.D. , as Chief Scientific Officer

| General news | No Comments
Dr. Scheer brings over 25 years of international life science experience in multiple disciplines, technologies and therapeutic areas Leuven, BELGIUM – 23 April 2020 – Aelin Therapeutics NV, an emerging…

Aelin Therapeutics will be attending the Novel Antimicrobials and AMR Diagnostics meeting in Berlin.

| General news | No Comments
Please join Els Beirnaert, CEO, presenting on Friday March 15thhttps://amr-conference.com/home/

Als we niet snel ingrijpen worden standaardingrepen binnenkort problematisch

| General news | No Comments
Els Beirnaert, CEO van Aelin Therapeutics in Z-talk https://kanaalz.knack.be/talk/als-we-niet-snel-ingrijpen-worden-standaardingrepen-binnenkort-problematisch-22-12-18/video-normal-1409969.html

Aelin Therapeutics pursues new cancer drugs

| General news | No Comments
The young biotech spin-off gains momentum with a VLAIO grant and an investor award Aelin Therapeutics announced today that it has been awarded close to 1M EUR in non-dilutive funding…

Aelin Therapeutics wins the LifeStars Award at the Jefferies 2018 London Healthcare Conference

| General news | No Comments
Yesterday at the Jefferies 2018 London Healthcare Conference, Aelin Therapeutics has been awarded the Life Stars award for EU Private Finance Raise of the year. The Jefferies conference is the largest…

Trapping Multidrug-Resistant Bacteria In Molecular Glue

| General news | No Comments
Researchers at VIB, KU Leuven and UZ Leuven devised a novel approach to develop antibacterial drugs. With antibiotic resistance on the rise worldwide, such new drugs are urgently needed. The…

Aggregating sequences that occur in many proteins constitute weak spots of bacterial proteostasis

| Anti bacterials, Scientific publications | No Comments
Aggregation is a sequence-specific process, nucleated by short aggregation-prone regions (APRs) that can be exploited to induce aggregation of proteins containing the same APR. Here, we find that most APRs…

New VIB start-up Aelin Therapeutics secures 27 M€

| General news | No Comments
New VIB start-up Aelin Therapeutics secures 27 M€ to exploit its proprietary Pept-in™ protein knockdown platform Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured…

Aelin Therapeutics awarded €2.3 million VLAIO research grant

| General news | No Comments
Funding will enable accelerated development of unique Pept™-in-based cancer therapeuticsLeuven, BELGIUM – 9 July 2020 – Aelin Therapeutics NV, an emerging biotechnology company focused on the discovery and development of…

Aelin Therapeutics appoints Alexander Scheer, Ph.D. , as Chief Scientific Officer

| General news | No Comments
Dr. Scheer brings over 25 years of international life science experience in multiple disciplines, technologies and therapeutic areas Leuven, BELGIUM – 23 April 2020 – Aelin Therapeutics NV, an emerging…

Aelin Therapeutics will be attending the Novel Antimicrobials and AMR Diagnostics meeting in Berlin.

| General news | No Comments
Please join Els Beirnaert, CEO, presenting on Friday March 15thhttps://amr-conference.com/home/

Als we niet snel ingrijpen worden standaardingrepen binnenkort problematisch

| General news | No Comments
Els Beirnaert, CEO van Aelin Therapeutics in Z-talk https://kanaalz.knack.be/talk/als-we-niet-snel-ingrijpen-worden-standaardingrepen-binnenkort-problematisch-22-12-18/video-normal-1409969.html

Aelin Therapeutics pursues new cancer drugs

| General news | No Comments
The young biotech spin-off gains momentum with a VLAIO grant and an investor award Aelin Therapeutics announced today that it has been awarded close to 1M EUR in non-dilutive funding…

Aelin Therapeutics wins the LifeStars Award at the Jefferies 2018 London Healthcare Conference

| General news | No Comments
Yesterday at the Jefferies 2018 London Healthcare Conference, Aelin Therapeutics has been awarded the Life Stars award for EU Private Finance Raise of the year. The Jefferies conference is the largest…

Trapping Multidrug-Resistant Bacteria In Molecular Glue

| General news | No Comments
Researchers at VIB, KU Leuven and UZ Leuven devised a novel approach to develop antibacterial drugs. With antibiotic resistance on the rise worldwide, such new drugs are urgently needed. The…

New VIB start-up Aelin Therapeutics secures 27 M€

| General news | No Comments
New VIB start-up Aelin Therapeutics secures 27 M€ to exploit its proprietary Pept-in™ protein knockdown platform Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured…

Aggregating sequences that occur in many proteins constitute weak spots of bacterial proteostasis

| Anti bacterials, Scientific publications | No Comments
Aggregation is a sequence-specific process, nucleated by short aggregation-prone regions (APRs) that can be exploited to induce aggregation of proteins containing the same APR. Here, we find that most APRs…

De novo design of a biologically active amyloid

| High value, undruggable targets, Scientific publications | No Comments
Amyloid aggregation is driven by short sequences within proteins that self-assemble into characteristic amyloid structures. About 30 human proteins are implicated in amyloid-associated diseases, but many more contain short sequences…

Protein aggregation as an antibiotic design strategy

| Anti bacterials, Scientific publications | No Comments
Taking advantage of the xenobiotic nature of bacterial infections, we tested whether the cytotoxicity of protein aggregation can be targeted to bacterial pathogens without affecting their mammalian hosts. In particular,…

Do you want to be the first to learn about Aelin Therapeutics developments?